Allianz Asset Management
NEOS

Allianz Asset Management’s Neos Therapeutics, Inc NEOS Stock Holding History

Allianz Asset Management’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-19,410
Closed -$161K – 2758
2018
Q1 		$161K Buy
+19,410
New +$185K ﹤0.01% 2588

Other funds holding NEOS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Allianz Asset Management's NEOS Position: Q2 2018 in Review

Allianz Asset Management sold out of Neos Therapeutics, Inc (NEOS) in Q2 2018, closing a stake of 19,410 shares — an estimated $161K sold.

Allianz Asset Management first reported a position in NEOS in Q1 2018 and held it in 1 quarter. The position peaked at $161K in Q1 2018. 73 funds tracked by Wall St. Rank hold NEOS as of Q2 2018.

  • Allianz Asset Management reported no remaining Neos Therapeutics, Inc position as of Q2 2018 after selling out during the quarter.
  • Allianz Asset Management sold 19,410 Neos Therapeutics, Inc shares in Q2 2018, an estimated $161K.
  • Allianz Asset Management first reported a position in Neos Therapeutics, Inc in Q1 2018 and held it in 1 quarter.
  • Allianz Asset Management's Neos Therapeutics, Inc position peaked at $161K in Q1 2018.
  • 73 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q2 2018.

Based on Allianz Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.